Interim Phase 2 Results from First-in-Class Combination of Invikafusp Alfa and TRODELVY® Selected for Oral Presentation at SITC 2026
STARt-002 is the first clinical study to combine a Vβ6-selective T-cell agonist with an ADC, pairing invikafusp alfa's selective T-cell activation with TRODELVY's TROP2-directed delivery of a cytotoxic payload Oral presentation will feature interim clinical results from two distinct...